These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16549901)

  • 41. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
    Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
    Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Low molecular heparin for treatment of venous thrombosis in two very low-birth-weight pre-term infants with genetic risk factors].
    Volz S; Schinzel H; Keune N; Neukirch M; Schmidtke S; Stopfkuchen H
    Klin Padiatr; 2006; 218(4):226-9. PubMed ID: 16819704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IV enoxaparin in pediatric and cardiac ICU patients.
    Cies JJ; Santos L; Chopra A
    Pediatr Crit Care Med; 2014 Feb; 15(2):e95-103. PubMed ID: 24335994
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates.
    Goldsmith R; Chan AK; Paes BA; Bhatt MD;
    J Perinatol; 2015 Oct; 35(10):852-4. PubMed ID: 26181722
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review.
    Ho SH; Wu JK; Hamilton DP; Dix DB; Wadsworth LD
    J Pediatr Hematol Oncol; 2004 Sep; 26(9):561-6. PubMed ID: 15342982
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound.
    Revel-Vilk S; Sharathkumar A; Massicotte P; Marzinotto V; Daneman A; Dix D; Chan A
    J Thromb Haemost; 2004 Jan; 2(1):42-6. PubMed ID: 14717964
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of low molecular weight heparin in pediatric patients: a prospective cohort study.
    Dix D; Andrew M; Marzinotto V; Charpentier K; Bridge S; Monagle P; deVeber G; Leaker M; Chan AK; Massicotte MP
    J Pediatr; 2000 Apr; 136(4):439-45. PubMed ID: 10753240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Subdural hemorrhages associated with antithrombotic therapy in infants with cerebral atrophy.
    Dang LT; Shavit JA; Singh RK; Joshi SM; Leber SM; Barks JD; Shellhaas RA
    Pediatrics; 2014 Sep; 134(3):e889-93. PubMed ID: 25113301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enoxaparin therapy for arterial thrombosis in infants with congenital heart disease.
    Bontadelli J; Moeller A; Schmugge M; Schraner T; Kretschmar O; Bauersfeld U; Bernet-Buettiker V; Albisetti M
    Intensive Care Med; 2007 Nov; 33(11):1978-84. PubMed ID: 17554520
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bullous hemorrhagic dermatosis distant from the site of heparin injection.
    Concha-Garzon M; Sotomayor-Lopez E; Solano-Lopez G; Fraga J; De Argila D
    Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526009
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Practice patterns in the management of pediatric iliofemoral arterial thrombosis.
    Vaughn AE; Hall JK; Harrison ML; Klein G; Diaz-Miron J; Yi JA; Acker SN
    Surgery; 2023 Oct; 174(4):940-945. PubMed ID: 37507305
    [TBL] [Abstract][Full Text] [Related]  

  • 52. LMWH - action-monitoring for all patients.
    Stief T
    Acta Paediatr; 2012 Aug; 101(8):e314. PubMed ID: 22537170
    [No Abstract]   [Full Text] [Related]  

  • 53. An eruption of angiokeratomas in the setting of enoxaparin injections.
    Ali H; Bennett DD; Muchard L
    Int J Dermatol; 2016 Oct; 55(10):e561-3. PubMed ID: 27126349
    [No Abstract]   [Full Text] [Related]  

  • 54. Enoxaparin-induced hepatotoxicity: an under-recognised complication of enoxaparin therapy.
    Pivarnik KA; Schiffman F; Sullivan J; Finn A
    BMJ Case Rep; 2016 Sep; 2016():. PubMed ID: 27664226
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Trilogy of SARS-CoV-2 in Pediatrics (Part 3): Thrombosis, Anticoagulant, and Antiplatelet Considerations.
    Tran VL; Parsons S; Varela CR
    J Pediatr Pharmacol Ther; 2021; 26(6):565-576. PubMed ID: 34421405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease.
    van Ommen CH; Albisetti M; Chan AK; Estepp J; Jaffray J; Kenet G; Young G; Dave J; Grosso MA; Duggal A
    Res Pract Thromb Haemost; 2020 Jul; 4(5):886-892. PubMed ID: 32685899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Critical Evaluation of Enoxaparin Dose Adjustment Guidelines in Children.
    Dinh CN; Moffett BS; Galati M; Lee-Kim Y; Yee DL; Mahoney D
    J Pediatr Pharmacol Ther; 2019; 24(2):128-133. PubMed ID: 31019405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced dosing of enoxaparin for venous thromboembolism in overweight and obese adolescents: a single institution retrospective review.
    Hoffman S; Braunreiter C
    Res Pract Thromb Haemost; 2017 Oct; 1(2):188-193. PubMed ID: 30046689
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.
    Yee DL; O'Brien SH; Young G
    Clin Pharmacokinet; 2013 Nov; 52(11):967-80. PubMed ID: 23797535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The development of evidence-based care recommendations to improve the safe use of anticoagulants in children.
    Barclay CA; Vonderhaar KJ; Clark EA
    J Pediatr Pharmacol Ther; 2012 Apr; 17(2):155-8. PubMed ID: 23118667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.